CA3258109A1 - LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDS - Google Patents

LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDS

Info

Publication number
CA3258109A1
CA3258109A1 CA3258109A CA3258109A CA3258109A1 CA 3258109 A1 CA3258109 A1 CA 3258109A1 CA 3258109 A CA3258109 A CA 3258109A CA 3258109 A CA3258109 A CA 3258109A CA 3258109 A1 CA3258109 A1 CA 3258109A1
Authority
CA
Canada
Prior art keywords
nucleic acid
lipid nanoparticles
acid delivery
molecule based
based lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3258109A
Other languages
English (en)
French (fr)
Inventor
Pieter Michele FRANSEN
Henricus Marie Janssen
Roy VAN DER MEEL
Egbert Willem Meijer
Willem Jan Menno MULDER
Basil Frank Maria de Waal
Stijn HOFSTRAAT
Original Assignee
Bio Trip BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Trip BV filed Critical Bio Trip BV
Publication of CA3258109A1 publication Critical patent/CA3258109A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/028—Polyamidoamines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3258109A 2022-06-03 2023-06-05 LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDS Pending CA3258109A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22177313.8 2022-06-03
EP22177313 2022-06-03
PCT/EP2023/064963 WO2023233042A1 (en) 2022-06-03 2023-06-05 Polyvalent molecule based lipid nanoparticles for nucleic acid delivery

Publications (1)

Publication Number Publication Date
CA3258109A1 true CA3258109A1 (en) 2023-12-07

Family

ID=81940594

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3258109A Pending CA3258109A1 (en) 2022-06-03 2023-06-05 LIPID NANOPARTICLES BASED ON MULTIPURPOSE MOLECULES FOR THE ADMINISTRATION OF NUCLEIC ACIDS

Country Status (10)

Country Link
US (1) US20250325491A1 (cg-RX-API-DMAC7.html)
EP (1) EP4531818A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025518282A (cg-RX-API-DMAC7.html)
KR (1) KR20250031158A (cg-RX-API-DMAC7.html)
CN (1) CN119522092A (cg-RX-API-DMAC7.html)
AU (1) AU2023278446A1 (cg-RX-API-DMAC7.html)
CA (1) CA3258109A1 (cg-RX-API-DMAC7.html)
IL (1) IL317412A (cg-RX-API-DMAC7.html)
MX (1) MX2024014961A (cg-RX-API-DMAC7.html)
WO (1) WO2023233042A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250121393A (ko) * 2022-12-12 2025-08-12 스타르나 테라퓨틱스 표적 전달을 위한 신규 화합물 및 이의 용도
US12343429B2 (en) 2023-10-05 2025-07-01 Nanovation Therapeutics Inc. Method of delivery of DNA or RNA cargo unshielded lipid nanoparticles and compositions thereof
WO2025245869A1 (zh) * 2024-05-31 2025-12-04 清华大学 含有精氨酸结构的可电离脂质分子、包含其的脂质纳米颗粒及其用途
CN119431176B (zh) * 2024-11-05 2026-02-13 汉信生物科技(苏州)有限公司 一种可电离阳离子脂质及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4995423B2 (ja) * 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
KR102764250B1 (ko) 2015-09-14 2025-02-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 지질양이온성 덴드리머 및 이의 용도
CN114656378A (zh) * 2016-05-16 2022-06-24 得克萨斯州大学系统董事会 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
JP7330994B2 (ja) 2017-11-21 2023-08-22 アイカーン スクール オブ メディスン アット マウント サイナイ 治療用ナノ生物学的組成物による訓練免疫の促進
CN113616602B (zh) * 2021-08-31 2022-05-10 中国药科大学 一种重组高密度脂蛋白-聚酰胺-胺纳米复合物、制法及应用

Also Published As

Publication number Publication date
MX2024014961A (es) 2025-01-09
CN119522092A (zh) 2025-02-25
JP2025518282A (ja) 2025-06-12
US20250325491A1 (en) 2025-10-23
EP4531818A1 (en) 2025-04-09
KR20250031158A (ko) 2025-03-06
WO2023233042A1 (en) 2023-12-07
IL317412A (en) 2025-02-01
AU2023278446A1 (en) 2024-10-31

Similar Documents

Publication Publication Date Title
IL317412A (en) Lipid nanoparticles based on multifunctional molecules for nucleic acid delivery
IL309502A (en) Lipid nanoparticles for nucleic acid delivery involving phosphatidylserine
ES2918001B2 (es) Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos
EP4346781A4 (en) DNA VECTOR DELIVERY USING LIPID NANOPARTICLES
EP4326236A4 (en) TISSUE-SPECIFIC NUCLEIC ACID DELIVERY BY MIXED CATIONIC LIPID PARTICLES
IL304759A (en) Lipids suitable for the transfer of nucleic acids
IL281653A (en) Nanoparticulate Lipid Formulations Including Cationic Lipid Peptides for Nucleic Acid Therapy
CY1125212T1 (el) Συνθεσεις τροποποιημενου mrna
MX350198B (es) Emulsiones aceite en agua que contienen acidos nucleicos.
PT2279254T (pt) Novas formulações lipídicas para entrega de ácido nucleico
WO2012157867A3 (ko) 초고속 멀티 모드 질량 분석을 위한 비행시간 기반 질량 현미경 시스템
AU2022296780A1 (en) Nucleic acid containing nanoparticles
EP4132586A4 (en) VECTORS FOR EFFICIENT DELIVERY OF NUCLEIC ACIDS
BRPI0922985A2 (pt) vetor de direcionamento (homing) de receptor de fator de crescimento epidérmico (egfr), método para tratamento de câncer caracterizado por células superexpressando egfr, composição farmacêutica para administração sistêmica.
CL2011002808A1 (es) Procedimiento para provocar una respuesta inmunitaria en al menos un miembro de las especies aviares que comprende la administracion de una composicion que comprende una molecula de acido nucleico y un vehiculo de liberacion liposomico cationico.
EP4069261A4 (en) PEPTIDE DOCKING VEHICLE FOR TARGETED NUCLEIC ACID DELIVERY
EP4158042A4 (en) NUCLEIC ACID CONSTRUCTS FOR PROTEIN PRODUCTION
WO2014134509A3 (en) Peptide-and amine-modified glucan particles for delivery of therapeutic cargoes
IL325550A (en) Ionizable dianhydrohexitol-based lipids for nucleic acid transport
AU2024349841A1 (en) Polymer nanoparticle compositions for non-viral gene delivery
EP4328318A4 (en) METHODS FOR CHARACTERIZATION OF MOLECULAR RELEASE PARTICLES
HK40112945A (en) Novel lipid nanoparticles for delivery of nucleic acids
HK40113134A (en) Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
HK40108274A (en) Tissue-specific nucleic acid delivery by mixed cationic lipid particles
CA3278449A1 (en) Novel ionizable lipid compounds for nucleic acid delivery

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20241202

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250404

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250404

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: SMALL ENTITY DECLARATION DETERMINED COMPLIANT

Effective date: 20250404

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250404

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250408

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - SMALL

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250530

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250530

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20260225

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20260225

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260527

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260527